Adults taking high doses of amphetamine-based medications for ADHD, such as Adderall, face a five-fold increased risk of developing psychosis or mania. The risk was highest for those taking 30 mg or more of dextroamphetamine, with 81% of psychosis or mania cases potentially avoidable by lowering the dose.

Researchers have discovered that nondeceptive placebos—placebos given with the full knowledge that they are placebos—can effectively manage stress, even when administered remotely. In a two-week randomized controlled trial, participants experiencing prolonged stress were divided into two groups: one group received nondeceptive placebos, while the other served as a control.

A meta-analysis suggests that high doses of psilocybin may alleviate depressive symptoms similarly to the SSRI drug escitalopram. While the effect size was small, psilocybin outperformed placebo in clinical trials, though study design flaws could have led to overestimated results. The findings indicate that psilocybin, particularly in high doses, may offer a new avenue for treating depression, comparable to existing antidepressants.

A new study shows that Cannabigerol (CBG) significantly reduces anxiety without the intoxicating effects of THC. The clinical trial found that 20 mg of CBG reduced anxiety and stress in participants, with memory enhancement as an unexpected benefit. The study highlights CBG’s potential as an alternative anxiety treatment. Further research is needed to confirm these findings and explore additional benefits.

A new study reveals that psilocybin, the active compound in magic mushrooms, temporarily disrupts brain networks involved in introspective thinking, like daydreaming and memory. These changes persist for weeks, potentially making the brain more flexible and improving mental health. The findings could pave the way for psilocybin-based therapies for depression and PTSD. The research underscores the importance of using these drugs under medical supervision.